

Data supplement for Grilo et al., Naltrexone-Bupropion Combination and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. *Am J Psychiatry* (doi: 10.1176/appi.ajp.20220267)

**TABLE S1.** Mixed model findings for primary outcomes

	Binge Eating Frequency (EDE Interview)	Binge Eating Frequency (EDE Questionnaire)	Percent Weight Loss
BWL	F(1,121)=5.86, p=0.02	F(1,163)=9.59, p=0.002	F(1,126)=12.78, p=0.0005
MED	F(1,121)=3.67, p=0.06	F(1,163)=6.11, p=0.02	F(1,126)=7.74, p=0.006
BWL*MED	F(1,121)=0.09, p=0.77	F(1,163)=0.14, p=0.71	F(1,126)=4.25, p=0.04
time	F(1,111)=239.39, p<0.0001	F(4,407)=92.84, p<0.0001	F(3,111)=12.56, p<0.0001
BWL*time	F(1,111)=24.34, p<0.0001	F(4,407)=5.99, p<0.0001	F(3,111)=10.70, p<0.0001
MED*time	F(1,111)=0.30, p=0.58	F(4,407)=2.57, p=0.04	F(3,111)=0.58, p=0.63
BWL*MED*time	F(1,111)=0.03, p=0.87	F(4,407)=1.08, p=0.37	F(3,111)=1.18, p=0.32

Note: The Eating Disorder Examination (EDE) interview was administered at the pretreatment and posttreatment assessments, and the Eating Disorder Examination Questionnaire was administered at the pretreatment, monthly, and posttreatment assessments. BWL=behavioral weight loss versus no behavioral weight loss; MED=naltrexone/bupropion versus placebo; time=assessment timepoints.